Pfizer to Withdraw Sickle-Cell Drug Oxbryta From Worldwide Markets Decision comes two years after acquiring the drug’s parent company, Global Blood Therapeutic, in a $5.4 billion deal By ...

Pfizer has announced the voluntary withdrawal of all lots of OXBRYTA (voxelotor) approved for treating sickle cell disease (SCD) from worldwide markets. The company is also discontinuing all ...

Oxbryta's withdrawal will be a "significant blow" to patients with sickle cell disease "who have been historically underserved," BMO Capital Markets analyst Evan Seigerman wrote in a research note ...

Pfizer said Wednesday that it was removing Oxbryta, a pill for the treatment of sickle cell disease, from all markets globally due to high risks of severe safety events, including deaths.

SOUTH SAN FRANCISCO, Calif., July 26, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that the Medicines and Healthcare products Regulatory Agency ...

In the second quarter of 2024, Oxbryta generated sales of $92 million, up 20% year-over-year. Pfizer added Oxbryta to its portfolio via its $5.4 billion buyout of Global Blood Therapeutics in 2022.

What the withdrawal of its sickle cell drug means for Pfizer, patients, and the FDA. The concerns behind the withdrawal were serious. The Food and Drug Administration approved Oxbryta in 2019, but ...

--Global Blood Therapeutics, Inc. today announced plans to expand the potential use of Oxbryta ® for the treatment of sickle cell disease in children ages 4 to 11 years, following a Type B ...

Oxbryta is a prescription drug used to treat sickle cell disease. Learn about the common, mild, and serious side effects it can cause and how to manage them. Health Conditions ...

Adakveo and Oxbryta could be revolutionary treatments, but each costs about $100,000 per year and must be taken for life. Share full article Red blood cells distorted by sickle-cell disease seen ...

First and only FDA-approved sickle hemoglobin polymerization inhibitor, a new class of therapy Oxbryta broadly indicated for the treatment of sickle cell disease in adults and children 12 years of ...

Intends to seek full marketing authorization for Oxbryta to treat hemolytic anemia in sickle cell disease. SOUTH SAN FRANCISCO, Calif., June 24, 2020-- Global Blood Therapeutics, Inc. today ...